PLoS ONE (Jan 2013)

A synthetic model of human beta-thalassemia erythropoiesis using CD34+ cells from healthy adult donors.

  • Y Terry Lee,
  • Ki Soon Kim,
  • Colleen Byrnes,
  • Jaira F de Vasconcellos,
  • Seung-Jae Noh,
  • Antoinette Rabel,
  • Emily R Meier,
  • Jeffery L Miller

DOI
https://doi.org/10.1371/journal.pone.0068307
Journal volume & issue
Vol. 8, no. 7
p. e68307

Abstract

Read online

Based upon the lack of clinical samples available for research in many laboratories worldwide, a significant gap exists between basic and clinical studies of beta-thalassemia major. To bridge this gap, we developed an artificially engineered model for human beta thalassemia by knocking down beta-globin gene and protein expression in cultured CD34+ cells obtained from healthy adults. Lentiviral-mediated transduction of beta-globin shRNA (beta-KD) caused imbalanced globin chain production. Beta-globin mRNA was reduced by 90% compared to controls, while alpha-globin mRNA levels were maintained. HPLC analyses revealed a 96% reduction in HbA with only a minor increase in HbF. During the terminal phases of differentiation (culture days 14-21), beta-KD cells demonstrated increased levels of insoluble alpha-globin, as well as activated caspase-3. The majority of the beta-KD cells underwent apoptosis around the polychromatophilic stage of maturation. GDF15, a marker of ineffective erythropoiesis in humans with thalassemia, was significantly increased in the culture supernatants from the beta-KD cells. Knockdown of beta-globin expression in cultured primary human erythroblasts provides a robust ex vivo model for beta-thalassemia.